β‐cell function after intervention was similar in patients with insulin‐ and sitagliptin‐treated LADA, regardless of the strength of autoimmunity. Further, participants with low levels of GAD antibodies did not experience progressive deterioration of β‐cell function over a 21‐month period. Taken together, these findings could be useful for clinicians’ choices of treatment in people with LADA (Diabetes, Obesity and Metabolism)
Diabetes News
Category: Treatment
Deintensification in older patients with type 2 diabetes: A systematic review of approaches, rates and outcomes
Available but limited evidence suggests that the benefits of deintensification outweigh the harm in older people with type 2 diabetes with or without comorbidities (Diabetes, Obesity and Metabolism)
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up
Participants with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had a lower risk of cardiovascular events than those who received standard therapy only during the prolonged period in which the glycated hemoglobin curves were separated (NEJM)
Use of sensor‐integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real‐world study in the UK
Real‐world UK data show that increasing automation of insulin suspension reduces hypoglycaemia exposure in people with Type 1 diabetes (Diabetic Medicine)
Adjunct Therapy in Type 1 Diabetes: A Survey to Uncover Unmet Needs and Patient Preferences Beyond HbA1c Measures
This survey highlights the importance of measures beyond HbA1c, such as treatment simplification and TIR, and patient preference for adjunct therapies that help address unmet needs in type 1 diabetes treatment (Diabetes Technology and Therapeutics)
First aid glucose administration routes for symptomatic hypoglycaemia
These results have important implications for individuals with symptoms of mild to moderate hypoglycaemia, their family members and first‐aid providers (Cochrane)
Implementation of Basal–Bolus Therapy in Type 2 Diabetes
Bolus insulin delivered by patch and pen using an algorithm-based weekly insulin dose titration significantly improved HbA1c in adults with type 2 diabetes, with improved subject and health care provider experience and preference for the patch (Diabetes Technology and Therapeutics)
Effect of hyperbaric oxygen therapy on the fatty acid composition and IGFBP-1 in insulin-dependent diabetes mellitus adult patients: a pilot study
Our results indicate that HBOT exerts beneficial effects in IDDM patients by improving the lipid profile and altering FA composition (Canadian Journal of Diabetes)
Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT‐M study
In participants not at HbA1c goal on a sub‐maximal dose of metformin, addition of sitagliptin at the time of metformin dose uptitration improved glycaemic response and HbA1c goal attainment, with similar safety and tolerability, compared to metformin uptitration alone (Diabetes, Obesity and Metabolism)
Longitudinal Changes in HbA1c following Treatment Intensification after Inadequate Response to Two Oral Antidiabetic Agents in Patients with Type 2 Diabetes
In patients with T2DM, intensification following A1c ≥7.0% on 2OADs was associated with a significant improvement in glycemic control. Patients intensified with insulin had a higher baseline A1c but greater A1c reduction than those intensified with a non‐insulin agent. However, A1c remained above 8.0% overall (Diabetes, Obesity and Metabolism)
Glycemic goal attainment and hypoglycemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real‐world results from the DELIVER Naïve cohort study
Among insulin‐naïve adults with T2D, Gla‐300 was associated with significantly better HbA1c reductions (latest value during 90–180‐day follow‐up) and similar or improved hypoglycemia outcomes (3‐ and 6‐month follow‐up) than Gla‐100 (Diabetes, Obesity and Metabolism)
A Type 1 diabetes technology pathway: consensus statement for the use of technology in Type 1 diabetes
This pathway is endorsed by UK‐wide clinical and patient associations and we recommend that providers and commissioners use it to ensure the right individual with diabetes has access to the right technology in a timely way to help achieve better outcomes (Diabetic Medicine)
Glycemic Control after Treatment Intensification in Patients with Type 2 Diabetes Uncontrolled on Two or More Non‐Insulin Antidiabetic Drugs in a Real‐World Setting
Despite intensification, most patients failed the glycaemic goal of HbA1c <7%. The reduction depended mainly on pre‐intensification HbA1c values, with small differences between drugs (Diabetes, Obesity and Metabolism)
The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm
The symposium, while acknowledging the need for newer antidiabetic drugs in specific situations and patient groups, recommended the continuation of SUs and metformin as the primary oral antidiabetic agents in resource-constrained regions of the world (Diabetes Therapy)
Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study
During DCCT/EDIC, higher insulin doses were associated with adverse trends in several cardiometabolic risk factors, even after multivariable adjustment, but not with incident CVD outcomes (Diabetes Care)
Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review
Several preclinical studies consistently showed that GLP-1 receptor agonists reduce infarct volume and improve the functional outcome after ischemic stroke. These beneficial effects appear to be mediated by anti-inflammatory, antioxidant, and anti-apoptotic actions of these agents (Diabetes Therapy)
Participants’ Experiences of, and Views About, Daytime Use of a Day-and-Night Hybrid Closed-Loop System in Real Life Settings
While participants reported substantial benefits to using the closed loop during the day, they also identified ways in which the technology could be refined and education and training tailored to optimize effective use. Our findings suggest that mainstreaming this technology will not necessarily lead to increased demands on clinical staff (Diabetes Technology and Therapeutics)
Effect of Remote Glucose Monitoring Utilizing Computerized Insulin Dose Adjustment Algorithms: A Pilot Project
Remote glucose monitoring utilizing computerized insulin dose adjustment algorithms saved time for both providers and patients while effectively improving glycemia (Diabetes Therapy)
Physician–patient communication at prescription of an additional oral drug for type 2 diabetes and its links to patient outcomes – new findings from the global IntroDia® study
Encouraging and patient-inclusive conversations at add-on moments may improve patient well-being and self-care outcomes. People with T2DM who attempted to delay additional medication reported poorer PPCQ and outcomes (Diabetes Research and Clinical Practice)
Insulin Bolus Administration in Insulin Pump Therapy: Effect of Bolus Delivery Speed on Insulin Absorption from Subcutaneous Tissue
Results suggest that insulin bolus delivery with fast delivery speed may result in more rapid insulin absorption and, thus, may provide a better control of meal-related glucose excursions than that obtained with bolus delivery using slow delivery speeds. Our findings may have important implications for the future design of the bolus delivery unit of insulin pumps (Diabetes Technology and Therapeutics)
- 1
- 2
- 3
- …
- 20
- Next Page »
Glycosmedia is also available as an App: